240 related articles for article (PubMed ID: 16081040)
1. Engineered alpha-synuclein prevents wild type and familial Parkin variant fibril formation.
Sode K; Usuzaka E; Kobayashi N; Ochiai S
Biochem Biophys Res Commun; 2005 Sep; 335(2):432-6. PubMed ID: 16081040
[TBL] [Abstract][Full Text] [Related]
2. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation.
Kessler JC; Rochet JC; Lansbury PT
Biochemistry; 2003 Jan; 42(3):672-8. PubMed ID: 12534279
[TBL] [Abstract][Full Text] [Related]
3. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
Li J; Uversky VN; Fink AL
Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
[TBL] [Abstract][Full Text] [Related]
4. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.
Uversky VN; Li J; Souillac P; Millett IS; Doniach S; Jakes R; Goedert M; Fink AL
J Biol Chem; 2002 Apr; 277(14):11970-8. PubMed ID: 11812782
[TBL] [Abstract][Full Text] [Related]
5. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.
Du HN; Tang L; Luo XY; Li HT; Hu J; Zhou JW; Hu HY
Biochemistry; 2003 Jul; 42(29):8870-8. PubMed ID: 12873148
[TBL] [Abstract][Full Text] [Related]
6. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
Rekas A; Adda CG; Andrew Aquilina J; Barnham KJ; Sunde M; Galatis D; Williamson NA; Masters CL; Anders RF; Robinson CV; Cappai R; Carver JA
J Mol Biol; 2004 Jul; 340(5):1167-83. PubMed ID: 15236975
[TBL] [Abstract][Full Text] [Related]
7. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
Foguel D; Suarez MC; Ferrão-Gonzales AD; Porto TC; Palmieri L; Einsiedler CM; Andrade LR; Lashuel HA; Lansbury PT; Kelly JW; Silva JL
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9831-6. PubMed ID: 12900507
[TBL] [Abstract][Full Text] [Related]
8. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
9. Raman spectroscopic characterization of secondary structure in natively unfolded proteins: alpha-synuclein.
Maiti NC; Apetri MM; Zagorski MG; Carey PR; Anderson VE
J Am Chem Soc; 2004 Mar; 126(8):2399-408. PubMed ID: 14982446
[TBL] [Abstract][Full Text] [Related]
10. In vitro preparation of prefibrillar intermediates of amyloid-beta and alpha-synuclein.
Lashuel HA; Grillo-Bosch D
Methods Mol Biol; 2005; 299():19-33. PubMed ID: 15980593
[TBL] [Abstract][Full Text] [Related]
11. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
Volles MJ; Lansbury PT
Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
[TBL] [Abstract][Full Text] [Related]
12. Neurodegenerative disease: amyloid pores from pathogenic mutations.
Lashuel HA; Hartley D; Petre BM; Walz T; Lansbury PT
Nature; 2002 Jul; 418(6895):291. PubMed ID: 12124613
[TBL] [Abstract][Full Text] [Related]
13. Oligopeptide-mediated acceleration of amyloid fibril formation of amyloid beta(Abeta) and alpha-synuclein fragment peptide (NAC).
Kuroda Y; Maeda Y; Hanaoka H; Miyamoto K; Nakagawa T
J Pept Sci; 2004 Jan; 10(1):8-17. PubMed ID: 14959887
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease: alpha-synuclein and parkin in protein aggregation and the reversal of unfolded protein stress.
Jakobsen LD; Jensen PH
Methods Mol Biol; 2003; 232():57-66. PubMed ID: 12840539
[No Abstract] [Full Text] [Related]
15. Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation.
Li HT; Du HN; Tang L; Hu J; Hu HY
Biopolymers; 2002 Aug; 64(4):221-6. PubMed ID: 12115139
[TBL] [Abstract][Full Text] [Related]
16. Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease.
Baptista MJ; Cookson MR; Miller DW
Neuroscientist; 2004 Feb; 10(1):63-72. PubMed ID: 14987449
[TBL] [Abstract][Full Text] [Related]
17. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T.
Li J; Uversky VN; Fink AL
Neurotoxicology; 2002 Oct; 23(4-5):553-67. PubMed ID: 12428728
[TBL] [Abstract][Full Text] [Related]
18. The E46K mutation in alpha-synuclein increases amyloid fibril formation.
Greenbaum EA; Graves CL; Mishizen-Eberz AJ; Lupoli MA; Lynch DR; Englander SW; Axelsen PH; Giasson BI
J Biol Chem; 2005 Mar; 280(9):7800-7. PubMed ID: 15632170
[TBL] [Abstract][Full Text] [Related]
19. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
Narhi L; Wood SJ; Steavenson S; Jiang Y; Wu GM; Anafi D; Kaufman SA; Martin F; Sitney K; Denis P; Louis JC; Wypych J; Biere AL; Citron M
J Biol Chem; 1999 Apr; 274(14):9843-6. PubMed ID: 10092675
[TBL] [Abstract][Full Text] [Related]
20. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
Park JY; Lansbury PT
Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
